Differences in health outcomes for high-need high-cost patients across high-income countries.


Journal

Health services research
ISSN: 1475-6773
Titre abrégé: Health Serv Res
Pays: United States
ID NLM: 0053006

Informations de publication

Date de publication:
12 2021
Historique:
revised: 06 07 2021
received: 15 03 2021
accepted: 12 07 2021
pubmed: 12 8 2021
medline: 15 12 2021
entrez: 11 8 2021
Statut: ppublish

Résumé

This study explores variations in outcomes of care for two types of patient personas-an older frail person recovering from a hip fracture and a multimorbid older patient with congestive heart failure (CHF) and diabetes. We used individual-level patient data from 11 health systems. We compared inpatient mortality, mortality, and readmission rates at 30, 90, and 365 days. For the hip fracture persona, we also calculated time to surgery. Outcomes were standardized by age and sex. Data was compiled by the International Collaborative on Costs, Outcomes and Needs in Care across 11 countries for the years 2016-2017 (or nearest): Australia, Canada, England, France, Germany, the Netherlands, New Zealand, Spain, Sweden, Switzerland, and the United States. The hip sample across ranged from 1859 patients in Aragon, Spain, to 42,849 in France. Mean age ranged from 81.2 in Switzerland to 84.7 in Australia, and the majority of hip patients across countries were female. The congestive heart failure (CHF) sample ranged from 742 patients in England to 21,803 in the United States. Mean age ranged from 77.2 in the United States to 80.3 in Sweden, and the majority of CHF patients were males. Average in-hospital mortality across countries was 4.1%. for the hip persona and 6.3% for the CHF persona. At the year mark, the mean mortality across all countries was 25.3% for the hip persona and 32.7% for CHF persona. Across both patient types, England reported the highest mortality at 1 year followed by the United States. Readmission rates for all periods were higher for the CHF persona than the hip persona. At 30 days, the average readmission rate for the hip persona was 13.8% and 27.6% for the CHF persona. Across 11 countries, there are meaningful differences in health system outcomes for two types of patients.

Identifiants

pubmed: 34378796
doi: 10.1111/1475-6773.13735
pmc: PMC8579207
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1347-1357

Informations de copyright

© 2021 The Authors. Health Services Research published by Wiley Periodicals LLC on behalf of Health Research and Educational Trust.

Références

Health Policy. 2013 Sep;112(1-2):100-9
pubmed: 23680074
Health Econ. 2012 Aug;21 Suppl 2:1-5
pubmed: 22815107
Health Serv Res. 2021 Dec;56 Suppl 3:1335-1346
pubmed: 34390254
CMAJ. 2014 Jan 7;186(1):E52-60
pubmed: 24246589
Arch Osteoporos. 2021 Feb 23;16(1):40
pubmed: 33624180
Med Care. 2015 Aug;53(8):686-91
pubmed: 26172938
JAMA Cardiol. 2019 May 1;4(5):444-453
pubmed: 30969316
Bone. 2014 Sep;66:171-7
pubmed: 24933345
Health Econ. 2015 Dec;24 Suppl 2:116-39
pubmed: 26633872
PLoS One. 2020 Feb 6;15(2):e0228425
pubmed: 32027676
Health Serv Res. 2021 Dec;56 Suppl 3:1347-1357
pubmed: 34378796
Bull World Health Organ. 2000;78(6):717-31
pubmed: 10916909
CMAJ. 2010 Oct 19;182(15):1609-16
pubmed: 20837683
Health Econ. 2008 Jan;17(1 Suppl):S1-8
pubmed: 18186039
Orthop Surg. 2020 Apr;12(2):457-462
pubmed: 32167674
Eur J Neurol. 2015 Feb;22(2):284-91, e25-6
pubmed: 25196190
Eur J Health Econ. 2005 Dec;Suppl:2-10
pubmed: 16270212
Eur J Public Health. 2015 Feb;25 Suppl 1:3-7
pubmed: 25690123
Eur J Public Health. 2015 Feb;25 Suppl 1:35-43
pubmed: 25690128
Health Serv Res. 2020 Apr;55(2):249-258
pubmed: 31984494
J Health Econ. 2013 Sep;32(5):909-21
pubmed: 23938273

Auteurs

Irene Papanicolas (I)

Department of Health Policy, London School of Economics, London, UK.

Kristen Riley (K)

Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Olukorede Abiona (O)

Centre for Health Economics Research and Evaluation (CHERE), University of Technology, Sydney, Australia.

Mina Arvin (M)

Scientific Center for Quality of Healthcare, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

Femke Atsma (F)

Scientific Center for Quality of Healthcare, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.

Enrique Bernal-Delgado (E)

Institute for Health Sciences in Aragon (IACS), Zaragoza, Aragon, Spain.

Nicholas Bowden (N)

Dunedin School of Medicine, University of Otago, Dunedin, Otago, New Zealand.

Carl Rudolf Blankart (CR)

KPM Center for Public Management, University of Bern, Bern, Switzerland.
Hamburg Center for Health Economics, Universität Hamburg, Hamburg, Germany.

Sarah Deeny (S)

The Health Foundation, London, UK.

Francisco Estupiñán-Romero (F)

Institute for Health Sciences in Aragon (IACS), Zaragoza, Aragon, Spain.

Robin Gauld (R)

Otago Business School, University of Otago, Dunedin, Otago, New Zealand.

Philip Haywood (P)

Centre for Health Economics Research and Evaluation (CHERE), University of Technology, Sydney, Australia.

Nils Janlov (N)

The Swedish Agency for Health and Care Services Analysis, Stockholm, Sweden.

Hannah Knight (H)

The Health Foundation, London, UK.

Luca Lorenzoni (L)

Health Division, Organisation for Economic Co-operation and Development (OECD), Paris, France.

Alberto Marino (A)

Department of Health Policy, London School of Economics, London, UK.
Health Division, Organisation for Economic Co-operation and Development (OECD), Paris, France.

Zeynep Or (Z)

Institute for Research and Documentation in Health Economics (IRDES), Paris, France.

Anne Penneau (A)

Institute for Research and Documentation in Health Economics (IRDES), Paris, France.

Andrew J Schoenfeld (AJ)

Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Kosta Shatrov (K)

KPM Center for Public Management, University of Bern, Bern, Switzerland.
Swiss Institute for Translational and Entrepreneurial Medicine, Bern, Switzerland.

Mai Stafford (M)

The Health Foundation, London, UK.

Onno van de Galien (O)

Zilveren Kruis, Leusden, The Netherlands.

Kees van Gool (K)

Centre for Health Economics Research and Evaluation (CHERE), University of Technology, Sydney, Australia.

Walter Wodchis (W)

Institute of Health Policy Management & Evaluation, University of Toronto, Toronto, Canada.

Ashish K Jha (AK)

Brown School of Public Health, Providence, Rhode Island, USA.

Jose F Figueroa (JF)

Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH